OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

← Orchid Cancer Appeal

2023-09-30-accounts

OUR IMPACT 1

Orchid Cancer Appeal Annual Report and Financial Statements 2022–2023

Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

2

Orchid Cancer Appeal Annual report and nancial statements fi 2022-2023

OUR IMPACT

3

Board of Trustees

Mr CS Osborne Chair Mr W Cohen Treasurer Mr D Badenoch Mr PG Bracher Mr S Harris Mr M Kibblewhite Professor RTD Oliver Mr P Norman (resigned 21 May 2023) Mr B Ayres Professor P Rajan (appointed 7 December 2023) Mr J Shedden (appointed 7 December 2023)

Chief Executive Mr A Orhan

Independent Examiner

Moore Kingston Smith LLP 6th Floor, 9 Appold Street, London EC2A 2AP

Accountants

JS2 Limited 1 Crown Square, Woking, Surrey GU21 6HR

Legal advisors

Registered Of ce

60 Gray’s Inn Road, London WC1X 8AQ

Tel 020 3745 7310 www.orchid-cancer.co.uk

Registered in England with the Charity Commission No.1080540

Company Limited by Guarantee Registered in England No. 3963360

Farrer & Co 66 Lincoln’s Inn Fields, London WC2A 3LH

Bankers

HSBC Plc 20 Electric Parade, George Lane, South Woodford, London E18 2LX

4 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

OUR IMPACT 5

Inside this report:

Letter from the Chair 6 CEO’s letter 7 The year in review 10 Fundraising 14 Our impact 22 Prostate cancer 22 Testicular cancer 26 Penile cancer 30 Research 32 The year ahead 36 Governance 40 Financial review 44 Formal statements 44 Independent Examiner’s information 44 Independent Examiner’s Report 45 Statement of nancial activities 47 fi Balance sheet 48 Statement of cash ows 49 fl Notes to the nancial statements 50 fi

6 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

Letter from the Chair

Orchid has now been a charity for 26 years. We exist to save men’s lives – sadly over 12,000 men in the UK lose their lives to male-speci fi c cancers (testicular, prostate and penile) each year – yet it’s a testament to our donors, fundraisers, volunteers and staff that many more are saved through awareness and early interventions.

Every year over 55,000 people are diagnosed with prostate, testicular or penile cancer and this number continues to increase.

Despite this:

And so, Orchid continues to educate people about male cancers, creating understanding about who is at risk and the signs and symptoms to look out for, so as many men as possible get an early diagnosis if they need one.

genito-urinary cancers. We were delighted when he was chosen to deliver the Kristin Henry Lecture at the Liverpool Pathology conference in June 2023 and again when he was presented with the Cunningham Medal by the British Division of the International Academy of Pathology in November 2023.

We congratulate Professor Berney and are immensely proud to have him with us, as we are to have all our staff and supporters – the individuals who donate or participate or volunteer; the Charitable Trusts and Foundations, the National Lottery Community Fund and companies who fund our projects; our project partners who help us deliver results; our Trustees, giving their time to make sure Orchid keeps on with its mission and of course all our staff.

And fi nally, I would like to mention Peter Norman who stepped down as a Trustee during the year and thank him for his most wonderful service and contribution to what we have achieved.

My sincere thanks to you all

Colin Osborne MBE, Chair

Orchid’s roots are in research and the research we have funded to date has helped to identify new ways to treat male cancers and improved our understanding of how male-speci fi c cancers behave.

We continue our support for the Robert Lane Tissue Bank which is an internationally important resource for research into penile, testicular, and prostate cancer, and is led by Professor Dan Berney who is an internationally recognised pathology expert in the three male

OUR IMPACT 7

Letter from the CEO

It has been another busy and productive year for Orchid. While our overall aim remains to develop innovative ways of meeting the needs of those at risk of and affected by prostate, testicular and penile cancer, we also recognise that some people face additional challenges to accessing services such as diagnosis and treatment. We aim to meet these needs by working collaboratively and thinking creatively to reach wider and new audiences, regardless of who they are, so they receive the information and support they need.

Highlights this year included:

The dedication of our staff, trustees, volunteers, patient advocates, partners and those who shared their stories enabled the charity to achieve so much.

I would like to take this opportunity to thank everyone who helped us in any way and highlight our wonderful donors. We could not have reached and supported so many people without both existing loyal and new donors whose support we really value. Thank you to each and every supporter.

Ali Orhan, CEO

8 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

33,977 people learnt about prostate cancer through the awareness interventions of Orchid Community Champions and experienced volunteers

OUR IMPAcr

Orchid Cancer Appeal | Annual report and nancial statements 2022-2023

10

The year in review

More than 55,000 men are diagnosed each year in the UK with prostate, testicular or penile cancer, and sadly around 12,000 die. Thankfully, however, many more will recover. To save lives, Orchid worked tirelessly throughout the year to help people better understand male cancer risk factors, potential signs and symptoms, as well as the bene fi ts of an early diagnosis.

We were excited to launch Take 3 , a new series of fi lms based on real patient experiences

OUR IMPACT 11

Through our Nurse-led services we supported those living with a diagnosis, and we continued to invest in world-class male cancer research to bene fi t both current and future generations.

Orchid’s Male Cancer Information Nurse Specialists gave personal support and guidance about concerns, the diagnostic pathway and treatment to those who called our con fi dential Freephone Male Cancer Helpline. This offers a joined-up service with some callers signposted to our unique testicular and penile cancer telephone service which offers a degree of anonymity to encourage men affected by these diseases to talk openly about their fears with a professional cancer counsellor. Peer support opportunities were delivered both virtually and in person.

As cancers found early are often the easiest to treat, education and awareness was a priority, especially as male cancer awareness remains low. We had a particular focus on reaching people from marginalised communities who may miss mainstream health messaging. 5,511 people had an opportunity to learn about male cancer by attending a Male Cancer Information Roadshow delivered in settings such as shopping centres and markets and in locations from Glasgow to Hastings, and Wake fi eld to Slough. Others had a chance to better understand their risk and what to look out for by attending talks and question and answer sessions in community groups or via our Health at Work programme.

Trans women are also at risk of prostate cancer, and we used the learnings from a focus group we ran with a group of trans women to inform a targeted series of social media posts. We also updated our website to make it more inclusive with the support of a charity trusted by the community.

----- Start of picture text -----
A focus group
for trans women
Orchid wants to learn about
what trans women want to know about
prostate cancer and the type of support they need.
PLEASE REGISTER HERE
working together
Orchid Cancer Appeal is registered in England with the Charity Commission No.1080540 Company Limited by Guarantee Registered in England No. 3963360 Healthworks Registered Charity Number: 1040370 Company Limited by Guarantee Number: 02952583
----- End of picture text -----

The learnings from a focus group with trans women helped inform a targeted series of social media posts

We are grateful for the support we receive from volunteers who help us spread the word about male cancers. A London based volunteer reached 7,675 people with information during the year, and 26,302 people in ten different locations in England received prostate cancer information from our Volunteer Community Champions who were trained as part of our Overcoming the Barriers to Engaging with Prostate Cancer project. Our Champions include those with lived experience, healthcare professionals, residents in prisons and those who simply want to help.

Reaching people digitally has become increasingly effective and 2023’s Male Cancer Awareness Week with its message of Small Change, Big Difference, and International Penile Cancer Awareness Day, were both driven by social media. In addition to the organic reach of social media during Male Cancer Awareness Week, paid advertising on Facebook enabled 236,970 people to see our message highlighting that responding to a concern about a change to your body quickly can make a big difference if cancer is detected.

Orchid’s awareness activities are supported by a portfolio of online, paper based and fi lm resources. December saw the launch of a new Orchid website to

Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

12

provide more accessible information to men and their loved ones as well as to healthcare professionals. Demand for information on both the Orchid website and our Your Privates testicular cancer microsite remained high throughout the year.

We were excited to launch a new series of fi lms called Take 3 based on three real patient experiences to help inform men of all ages about the signs, symptoms and risk factors of prostate, penile and testicular cancers, and the need to seek help from a healthcare professional promptly if concerned. This was complemented by a new booklet describing nine real life encounters designed to get people thinking – and talking – about these male-speci fi c cancers. Orchid had an advisory role in a short fi lm called Ignore It which was produced by penile cancer survivor Mr Richard Stamp and funded by eUROGEN.

A new booklet describing nine real life encounters was designed to get people thinking – and talking – about male-speci fi c cancers

Orchid works closely with eUROGEN a European organisation which is dedicated to improving the outcomes for rare urological conditions by enabling equitable access to diagnosis, treatment, and care for patients across Europe. Two penile cancer advocates supported by Orchid were involved in updating the current EAU Guidelines for penile cancer, a huge achievement, providing a much better recognition of the long-term issues which men may experience as a result of treatment and the need to expand the support which is currently available.

Orchid collaborated throughout the year with health and social care professionals, policy makers and other cancer charities to bring about positive change for men and their families. Examples include helping recruit Black African and Black Caribbean men to share their experience of prostate cancer on Prostate Cancer Research’s new Infopool, and as part of our collaboration with the Testicular Cancer Network, Orchid Nurse Rob Cornes attended the National Germ Cell Meeting in Glasgow attended by around 130 clinicians and specialist nurses where he helped chair a session on how members are working together to save lives.

Funding research is vital to help understand why men develop male cancers and to improve the way in which they are diagnosed and treated. Orchid continued support for the Robert Lane Tissue Bank which is led by Professor Dan Berney whose work is focused on the pathology and natural history of prostate, testicular and penile cancer, translating basic research into practical treatments for patients with novel tests and bespoke predictive treatments. A grant was also agreed for new prostate cancer research to be funded by donations to the Innovation Research Project and which will begin in the new fi nancial year.

OUR IMPACT

13

December saw the launch of Orchid’s new website to provide more accessible information to men and their loved ones as well as to healthcare professionals

14 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

OUR IMPACT

15

350,906 accounts were reached through Orchid’s fi ve social media platforms

Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

16

Fundraising

Orchid is committed to fundraising from diverse income streams to ensure adequate income is received to fund our work to save lives from prostate, testicular and penile cancers. A total of £730,024 was raised during the year, and we thank each and every one of our wonderful supporters who gave during the fi nancial year, be they individuals, community groups, sports clubs, schools, companies, charitable trusts and foundations or The National Lottery Community Fund.

A new fundraising lea fl et was developed to encourage donations

OUR IMPACT 17

So many people supported Orchid during the year because they have been touched by male cancer themselves, or they raised funds in memory of loved ones. Payroll giving and both new and regular donors provided a valuable source of unrestricted income, as did the gifts given in Wills. A new fundraising lea fl et was developed to encourage donations.

It is quite humbling to view people’s dedication to our cause. This is why the Orchid team were there to cheer participants on at major events such as the London Marathon and Landmarks Half Marathon, as well as at Orchid’s own events including our fi rst Willy Waddle in Edinburgh and one in London. Our small fundraising team also helped and encouraged our many supporters from right across the UK who organised so many different fundraising activities such as cake sales, the Twyford

Orchid team were there to cheer on participants at major events such as the London Marathon and Landmarks Half Marathon

Beer Festival, a large beard competition, a new ’Bollox and Boots’ event, a classic car event, or who challenged themselves via cycling, walking, climbing, or running events. Each person helped Orchid to make a difference.

There were some signi fi cant grants received during the year from Charitable Trusts and Companies towards delivering Nurse-led services to support those affected, to raise awareness through Male Cancer Information Roadshows in the heart of local communities, in faith settings and via social media, to develop new fi lms, and to fund a new Four Nations Penile Cancer Programme to start in the new fi nancial year. Funding was also received to fund male cancer research.

Incorporating learnings is important across the charity. Throughout the year Orchid staff and Trustees continued to review our fundraising activities and sought to identify new opportunities to ensure we retain as diverse and cost-effective fundraising base as possible to balance risk in the years ahead.

Orchid continually strives to meet and maintain high standards in all areas of fundraising and recognises the importance of listening to and putting supporters at the heart of all we do. We are registered with the Fundraising Regulator and adhere to the Code of Fundraising Practice when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising and other professional bodies. Orchid operates a clear and stringent complaints handling procedure that is reported to the Chief Executive and the Board of Trustees.

As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with any external agencies we engage to

18 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

help us or who raise funds for the Charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves.

During the year we did not receive any complaints in relation to our fundraising activities. We remain committed to improving our practice, learning from supporter feedback.

Small Change, Big Difference

Orchid’s Male Cancer Awareness Week successfully raises the pro fi le of prostate, testicular and penile cancer each year. In 2023 it was launched by Orchid Patron Steve Davis OBE, and included a fundraising ask for the rst time.

The Week was themed Small Change, Big Difference and was delivered mainly digitally. Posts about each male-speci fi c cancer across all social media platforms throughout the Week highlighted the small changes to men’s bodies which could be a symptom of that cancer.

As well as highlighting the difference an early diagnosis can make, the posts also showed the difference making a donation or giving your small change to Orchid would make, linking donations to the Nurse-led services and the male cancer research the charity funds.

It also provided an opportunity for supporters to fundraise under the umbrella of Small Change, Big Difference.

OUR IMPACT 19

Orchid’s Male Cancer Awareness Week provided an opportunity for supporters to fundraise under the umbrella theme of Small Change, Big Difference

20 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

OUR IMPACT

21

32,691 male cancer lea fl ets, booklets and posters were ordered or requested by individuals, companies, educators, and healthcare professionals

22 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

Our impact: Prostate cancer

Over 52,000 people are diagnosed with prostate cancer in the UK annually, that’s more than 140 every day. Sadly, there are 11,855 deaths from prostate cancer each year with 10-year survival at around 78%. According to CRUK, 1 in 6 UK males (born in the 1960s) will be diagnosed with prostate cancer in their lifetime, although the most commonly accepted statistic for general risk remains 1 in 8.

With more and more men being diagnosed with prostate cancer it is becoming more essential to correctly identify those who may be at risk of disease progression and those with mild or inactive disease. One of the interesting directions that this may take is so called liquid biopsies – the sampling of circulating cancer cells within the blood. Orchid has helped fund research into circulating tumour cells or CTCs and this method along with a more frequent use of MRI scans to identify potential areas of prostate cancer may improve medical assessment dramatically and reduce the side effects men may experience from cancer treatment.

One of the greatest challenges around prostate cancer remains the unequal risk of this cancer among Black African and Black Caribbean men who are twice as likely to develop prostate cancer than Caucasian men. Creating awareness in this community and helping support Black men diagnosed with prostate cancer is crucial. Although there are more than a hundred prostate cancer support groups in the UK, the Black community remains underrepresented.

A need also exists to reach trans women and non-binary people assigned male at birth with prostate cancer messaging, as they too can be diagnosed with this cancer.

In addition, those men with minimal risk of disease progression are likely to be managed by active surveillance. This is an option that is likely to increase dramatically over the next few years and one which Orchid has already created information about. Some men who are put on active surveillance may take 6-months or more to adjust to the fact that their cancer does not require immediate treatment and Orchid has responded to the need for information and support to help them.

OUR IMPACT 23

Spotlight on Let’s Talk Prostate Cancer Campaign

One in four Black African and Black Caribbean men will get prostate cancer in their lifetime, compared to one in eight Caucasian men, and tackling health inequalities is at the heart of Orchid’s work.

Orchid was therefore proud to be invited by Astellas Pharma Limited to host a parliamentary workshop to hear from Black African and Black Caribbean men who are living with prostate cancer about their personal experiences of care.

The voices of these men informed the writing of the report ‘1 in 4 Black men. Turning the tide on health inequalities in prostate cancer care’ with its important recommendations which are being considered by national parliamentarians and policy makers.

The workshop took place in March 2023 and all men present spoke with great passion about their prostate cancer journeys. Whilst there were many different experiences expressed, there was complete consensus that health inequalities associated with prostate cancer are not adequately prioritised or given the attention they should be.

Attendees felt men from diverse backgrounds could not easily engage with public prostate cancer messaging, and that they were not involved in their development. They found that the 1 in 4 statistic is not

suf fi ciently prominent. Messaging does not feature Black African and Black Caribbean men in images and it lacks cultural awareness / sensitivity. Furthermore, the men felt that the stigma around prostate cancer diagnosis and the use of a Digital Rectal Examination, and the potential side effects of treatment, which could both be barriers to engaging, have not been adequately addressed. Also expressed were the dif fi culties encountered asking GPs for a PSA test, which were often only offered based on age even when men highlighted their increased risk / family history.

Men also shared that there is a lack of easy to understand and culturally appropriate information at the point of diagnosis. This led to a lack of understanding about their treatment pathway and any potential side effects of treatment, and when they expressed a treatment preference, they felt their views were not always listened to and felt under pressure to have certain treatment.

The report, written taking the view of these men into account along with research of the prostate cancer policy landscape, sets out key recommendations to help push prostate cancer and the unequal risk of Black men up the agenda. The report has been well received and the recommendations are currently being discussed with parliamentarians and policy makers.

Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

24

7,041 people had a one-to-one interaction with Orchid Community Champion or volunteer

OUR IMPAcr 2S

26 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

Our impact: Penile cancer

Penile cancer is exceptionally rare in the UK with around 700 men being diagnosed each year. Around 170 men will lose their lives to the disease although 68% of men will survive 10 years following their diagnosis.

Out of the three male-speci fi c cancers, penile cancer has the potential to cause the most physically and psychologically damaging side effects, as all curative treatment will involve some form of surgery to the penis itself. This can be minimally invasive but may also involve partial or total amputation of the penis resulting in a radical change in body image and sexual function.

Due to its intimate nature up to 50% of men will delay seeking treatment. Delaying penile cancer treatment can lead to disease progression of the primary tumour such that organ-sparing surgery may no longer be feasible. In addition, 20-25% of penile cancer may be misdiagnosed with men being referred to dermatologists and sexual health clinics.

Treatment is performed at specialist regional treatment centres in the UK with dedicated teams performing penile sparing surgery.

The main challenges for Orchid around penile cancer are creating awareness of the disease - many people do not realise penile cancer exists, and the isolation which men may feel following treatment. Most men will never meet another man affected by penile cancer due to its rarity therefore missing out on invaluable peer support.

counselling service to support men and wherever possible has created events to offer peer support, as well as supporting and encouraging allied healthcare professionals in the creation of regional support groups.

With 83 cases a year, there is a higher incidence of penile cancer in Scotland in comparison to the rest of the UK, and those affected by penile cancer in Scotland are also being diagnosed at a younger age. A penile cancer diagnosis can be psychologically devastating, and treatment can be challenging especially if the diagnosis has been made at a late stage. Orchid has signi fi cant experience of educating people about the signs and symptoms of penile cancer, as well as understanding the complex issues involved in supporting penile cancer patients.

Whilst we do not as yet know why Scotland has a higher incidence proportionally than the rest of the UK, we do know that many people have not heard of penile cancer, let alone know what potential symptoms might be. This is why Orchid identi fi ed the need to deliver a project to put penile cancer on the agenda in Scotland, and whilst delivery of this speci fi c piece of work is complete, many of the elements have now been brought into Orchid’s core services.

We are delighted that funding has been received to deliver the Four Nations Penile Cancer programme from October 2023. The aim of this Nurse-led initiative is to raise the pro fi le of penile cancer in the UK and improve support for anyone who has been affected by the disease.

In addition, there is an unmet need to support these men psychologically. When men realise that they may need psychological help such as counselling there is often a severe delay in referral. Orchid has therefore focused on the development of a telephone

OUR IMPACT 27

Spotlight on Penile cancer animation for EAU

Over the last few years, Orchid Nurse Rob Cornes has been working collaboratively with both the European Reference Network for Rare Urogenital Disease (ERN eUROGEN) and the European Association of Urology Patient Advocacy Group (EAU EPAG), part of the EAU Patient Of fi ce initiative.

The Patient Of fi ce is dedicated to promoting advocacy for patients being treated for urological conditions. Rob is a patient advocate for testicular and penile cancer for both these groups.

Last year with the help of Orchid, the EAU Patient Of fi ce received funding from eUROGEN to create an informative animated video discussing penile cancer to complement the EAU video library of urology.

The aim was to include both an informative and honest overview of penile cancer diagnosis and treatment, as well as information about potential side effects in lay person’s terms. It describes the most common approach to diagnosing and treating penile cancer.

Rob was particularly delighted to be able to include a section which promotes the need for men diagnosed with penile cancer to obtain psychological support.

As part of the funding a Spanish language version was also created.

Both animations have proved extremely popular with a combined viewing of around 20,000 views, as well as over 50 positive comments from both urologists and patients who have viewed it.

A script was written by Orchid Nurse Rob which was then reviewed by three urology consultants specialising in penile cancer treatment. Once the script had been fi nalised it was also reviewed by a lay person panel and then put into production.

Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

28

5,511 people had the opportunity to learn about male cancer by attending an Orchid Male Cancer Information Roadshow.

OUR IMPAcr 29

30 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

Our impact: Testicular cancer

Testicular cancer is rare with around 2,300-2,400 diagnoses each year in the UK. Around 60 men will die each year from testicular cancer although it remains potentially the most treatable and curable type of cancer with over 90% of men surviving 10 years.

Testicular cancer tends to affect a younger age group than most other cancers, with nearly 50% of men diagnosed under the age of 35, and 80% of those diagnosed between the ages of 15-45. This means that testicular cancer will often affect men at a stage of their life where they may be starting a family or career, or just consolidating their place in life. Treatment occurs quickly with men often being diagnosed and treated within a few weeks. As well as surgery to remove the affected testicle, treatment may also involve chemotherapy. In addition to temporary side effects, chemotherapy can increase the risk of cardiovascular disease in later life.

Orchid has consistently supported the biggest testicular cancer support group in the UK, which is coordinated by several Specialist Nurses in London, both physically and virtually. In addition, the creation of Orchid’s telephone counselling service allows men to access psychological support without the necessity of waiting for extended periods of time. Orchid also continues to work with the Testicular Cancer Network to improve the resources available to those affected by testicular cancer throughout the UK.

Challenges around testicular cancer involve supporting men in adjustment to life following treatment. Many men will only realise the full implication of their cancer journey when treatment ends and may not be able to access either peer support or psychological support.

OUR IMPACT 31

Spotlight on The Know Your Body Project

Partnership working is important for Orchid to ensure we reach as many people as possible at risk of testicular cancer. The charity was therefore proud to work collaboratively with Ansar Projects and CoppaFeel! to create a series of accessible resources about testicular and breast cancer for people with learning disabilities.

49% of all deaths in people with a learning disability are deemed to be avoidable and 8% of these deaths were caused by cancer (The London King’s College Learning from Lives and Deaths – People with a learning disability and autistic people LeDeR 2021 report).

The ‘Know Your Body’ resources were launched in October 2022 and are the fi rst of their kind. These new resources were developed in response to the need for information for people with a learning disability to know their body and to seek medical advice when they notice changes at an earlier stage.

They include accessible testicular and breast cancer information packs, self-checking cards, testicular and breast cancer symptom guides, self-checking social stories and information on what to expect if you notice a change.

The ‘Know Your Body’ accessible resources were shortlisted as a fi nalist in the Breaking Down Barriers award at the 2023 National Learning Disabilities and Autism Awards.

We were also pleased that the resources were referenced in the Learning from lives and deaths – People with a learning disability and autistic people (LeDeR) Action from learning report 2022/23 , taking the resources to a wider audience.

32 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

Our impact: Research

Orchid was pleased to continue to support the work of the Robert Lane Tissue Bank during the year.

Highlights of the year

Over 30 papers were published from the group in the year. Many of these relate to work done on tissue from the Robert Lane Tissue Bank in the past and donated over 10 years ago yet still in clinical use. Professor Berney now has over 300 papers.

Prostate cancer

In collaboration with Professor G Attard at University College London the team have processed 700 cases from the groundbreaking STAMPEDE clinical trial which aims to assess new treatment approaches for people affected by high-risk prostate cancer. Ms Larissa Mendez who is a histopathologist passed her PhD in September 2023 on this cohort and numerous publications are planned.

Further work continues to be published from the Trans-Atlantic prostate group cohort into early-stage prostate cancer, with a publication on how best to measure the size of prostate cancer in biopsies that will affect management.

The team are delighted to announce a collaboration with the Institute of Cancer Research to collect further samples of prostate cancer from recent clinical trials. This will support Orchid work and will focus (among others) on the PACE-B trial which found that men undergoing treatment for prostate cancer could be safely given far less radiotherapy.

Testis cancer

The main success of the year in the fi eld of testis cancer was the publication of the fi rst paper from the collaboration with a team at the University of Copenhagen in Denmark into risk factors to predict whether testis cancer will come back and whether chemotherapy should be offered in seminoma (a common type of testis cancer). This paper was published in September 2023 in the highly prestigious Journal of Clinical Oncology. This work will directly affect the decisions on who gets chemotherapy after removal of the cancer in surgery. This fi gure from the paper shows how testicular seminoma can be strati fi ed into separate groups. The low-risk groups can be treated expectantly while the high risk groups might consider chemotherapy.

Professor Berney is lead for the testis International Collaboration on cancer reporting. This work ensures that pathology reports on testis cancer are standardised worldwide.

With the support of both the Genito-Urinary Pathology Society (GUPS) and the International Society of Urological Pathologists (ISUP), Professor Berney has set up a new group to examine the 'sex cord stromal tumours' of the testis. These rare tumours are not well understood, may be malignant and are resistant to treatment. He is the lead on an international meeting in Baltimore in 2024 about these tumours and hopes to make advances in this challenging area.

OUR IMPACT 33

Professor Dan Berney

Histopathology, a leading journal in the fi eld. He is Past Secretary of the International Society of Urological Pathologists (ISUP) , Past Secretary and President of the British Society of Urological Pathologists (BAUP) and Past International Secretary of the British Division of the International Academy of pathologists (BDIAP).

The Robert Lane Tissue Bank is led by Professor Dan Berney who is one of the world’s leading genito-urinary pathologists. The Tissue Bank carries out translational work which aims to link molecular and pathological data with clinical trials. The aim of the team is to curate a bespoke Tissue Bank concentrating on the three male cancers. In summary, it:

• Professor Berney has over 300 per reviewed publications and numerous book chapters on urological pathology. He has an H score of 84 (i.e. he has published 84 articles each of which has been cited at least 84 times) and his work has been cited over 15,000 times. Furthermore, he had 23 publications in the last 18 months.

Professor Yong-Jie Lu

34 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

OUR IMPACT

35

33,100 male cancer lea fl ets, booklets and posters were distributed through awareness activities such as Roadshows, Volunteer Community Champion community outreach, talks and presentations

36 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

The year ahead

Cancers diagnosed at an early stage are more likely to be treated successfully which means that raising awareness of the risk factors, signs and symptoms and the bene fi ts of an early diagnosis remained a priority as we entered the new fi nancial year. All work will be delivered in line with our organisational Strategy October 2022 to September 2026. Funding has been received and plans are in place to deliver several new and transformational initiatives, and to further develop existing work.

Keeping the faith

We will be working with faith leaders in London to raise awareness of prostate cancer amongst the Black African and Black Caribbean men in their congregations who are at increased risk of this cancer and we will equip them to better support those living with a diagnosis. We are also planning a social media campaign around the theme of “Warn a Brother” to encourage Black African and Black Caribbean men to share information about prostate cancer with their friends and family.

Orchid on lm

Films are in development to highlight prostate cancer and to get people talking about this cancer which affects over 52,000 people each year. We will also increase our outreach to trans women to make sure they gain a better understanding of their prostate cancer risk and know the support and information available to them including from Orchid.

On the road again

Male Cancer Information Roadshows are an established part of our community outreach, through which we take information right into the heart of communities. These will be delivered in targeted communities as funding becomes available. We will continue to offer male cancer talks and presentations to community groups and one priority for the year will be to deliver talks to the Deaf community supported by a British Sign Language interpreter to reduce inequality.

We are the champions

We will also continue to recruit, train and support Volunteer Community Champions as part of the National Lottery Community Fund project “Overcoming the Barriers to Engaging with Prostate Cancer”. Our Champions cascade important messages in their own

communities and workplaces, and we will explore how this work can be sustainable after funding for the project ends in May 2024, including upskilling Champions further about testicular and penile cancer alongside their knowledge of prostate cancer. Independent evaluation has been running throughout the project, and learnings will be shared with stakeholders and interested parties via a report after the project ends.

A week and a day

Orchid’s Male Cancer Awareness Week will take place between 16-22 September 2024, with International Penile Cancer Awareness Day on 20 September 2024.

Helpline focus

Supporting those affected by male cancer is also a high priority for the coming year. We are exploring increasing the hours of our Freephone National Male Cancer Helpline with the aim of missing fewer calls. Our commitment to delivering and co-facilitating peer support opportunities both in person and virtually remains, and we will continue to offer a telephone counselling service to those affected by penile or testicular cancer.

Four Nations

A new Four Nations Penile Cancer Programme started at the beginning of October led by Sinéad Collins who joined Orchid as a Male Cancer Information Nurse Specialist – Penile Cancer. Through this programme we will raise the pro fi le of penile cancer in the UK and improve support for anyone who has been affected by the disease.

Improved patient journey

Orchid Nurse Rob Cornes will continue to work with healthcare professionals both in the UK and beyond to improve the patient journey for those affected by male

OUR IMPACT 37

cancer. Orchid resources and services will be promoted throughout the year to healthcare professionals working in the relevant fi elds throughout the UK. Rob Cornes plans to work with the Testicular Cancer Network to produce an evidence-based guideline for testicular self-examination in the coming year.

Supported by penile cancer patient advocates, Rob Cornes, who is a member of the European Association of Urology Patient Advocacy Group and the European Reference Network eUROGEN European Patient Advocacy Group representing both testicular and penile cancer on behalf of Orchid, will continue to work to improve the patient experience for those affected by these two rare cancers. This work will include being involved in the updating of the European Association of Urology Testicular Cancer Guidelines as a patient advocate.

More social

Social media will be used to relay male cancer messages, promote our educational fi lms, to drive followers to the Orchid website / Your Privates testicular cancer microsite, to view, order or download resources and to help promote fundraising activities. The number of followers on all platforms has increased, and we aim to grow this further. Activity is planned incorporating learnings of the last year where we saw most reaction in response to personal stories and awareness.

Rooted in research

Orchid’s roots are in male cancer research, and we will continue to invest in innovative research. Trustees have agreed new funding for the year for the Robert Lane Tissue Bank, led by Professor Dan Berney MB B Chir, MA, FRCPath which is an internationally important resource for research into penile, testicular, and prostate cancer. Funding has also been agreed for new research into the characterisation of the anaerobic microbiome

and genomic methylation status of prostate cancer patients experiencing active Vitamin D and K2 de fi ciency: prevention, risk strati fi cation, diagnosis, and treatment potential, led by Dr Belinda Nedjai.

Measuring up

In the coming year we will be working to improve the way in which we measure activities and their impact so we can better evidence the difference our work makes.

Orchid recognises its responsibility to reduce its carbon and environmental footprint and will continue to monitor its activities in relation to our Environmental Policy.

Diverse income streams

Led by a new Head of Fundraising, our fundraising strategy for 2023-2024 will focus on generating income from diverse income streams to secure adequate funding at the best possible return on investment to ensure we can deliver plans for the years ahead. We will also explore new income generating opportunities and encourage people to take part in our unique Willy Waddles planned for Edinburgh and London in the summer months. Applications will be submitted to Charitable Trusts and Foundations on a rolling basis, carrying out research to identify new potential supporters. We will work in partnership with our corporate supporters to meet their needs as well as Orchid’s.

Orchid’s work is only possible because of the generosity of our supporters, and we will look after them in every way we can. We will continue to offer the best possible support to our corporate partners, the Charitable Trusts and Foundations who give to us, and all the individuals and community groups who support us with donations and fundraise on our behalf. We are grateful to everyone who contributed towards our work in the last year, as well as to those who will support us in the year ahead.

38 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

2,893 men, women and healthcare professionals had in-depth support or information directly from an Orchid Nurse / Male Cancer Information Manager

OUR IMPAcr 39 *?

40 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

Governance

Orchid’s aim is to provide greater knowledge and awareness about male speci fi c cancers by funding scienti fi c and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing information about them to people throughout the UK.

Objects, operating context and activities

Objects

Over 55,000 people in the UK are diagnosed with prostate, testicular or penile cancer every year and sadly this number is increasing. Orchid’s aim is to provide greater knowledge and awareness about male speci fi c cancers by funding integrated scienti fi c and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing eye-catching, easy to understand information about them to people throughout the UK, thereby helping to ensure a better quality of life for those affected.

Operating context and activities

Orchid's aim is to offer the best possible care and support for men and their families through awareness and education programmes, to promote better understanding of the signs and symptoms of these cancers, to encourage an early diagnosis and improved outcomes and to ensure the best possible care through our in fl uence at a local and national level. Through funding world class research, our aim is to improve our understanding of male cancers, how they work, possible causes and to identify new treatments and enhance care. Support and

information delivered by our Nurse Specialists and Community Engagement Team enables people interested in or affected by male cancers to have the best possible outcome.

Structure, governance and management

Duly registered as a Charity, Orchid is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association.

Trustees are recruited on the recommendation of incumbent members of the Board, commensurate with the Chair’s aim to maintain a balanced composition. Trustees acknowledge the need to increase diversity on the Board and are exploring the best ways to do this. Applications from individuals seeking to become a Trustee will be considered as and when appropriate by the Board. The Board meet four times during the year and, at the Annual General Meeting, as required by the constitution, one third of the Trustees (or the nearest number thereto) retire from of fi ce in rotation, in order of longevity of appointment and are eligible to be reappointed.

Trustees continued to meet virtually for most meetings held during 2022-2023.

OUR IMPACT 41

Trustee training and induction

On appointment, Trustees are offered a comprehensive induction programme which includes a meeting with the lead programme researchers and visit to the research programmes. In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive advises Trustees of opportunities that will increase their general understanding of voluntary sector, healthcare and/or medical research issues.

Delegation and decisionmaking

The decision-making process operates as follows:

At the strategic level, the Board of Trustees regularly reviews Orchid’s direction in the wider context of medical charities, requiring the Chief Executive to identify relevant key issues and present options for its consideration. Due governance remains a key requirement.

The Finance Committee is responsible for the fi nancial oversight of the Charity including budgeting, fi nancial planning and monitoring as well as fi nancial reporting and the creation and monitoring of internal controls and accounting policies. It presents a report to the Board at each of its meetings. As at 30 September 2023, it comprised the Honorary Treasurer, Mr W Cohen,

Mr C Osborne, Mr M Kibblewhite, Mr S Seymour and Mr S Harris.

At the operational level, the Board delegates the day-to-day running of the Charity to the Chief Executive, requiring him to deliver every aspect of governance, planning and performance in accordance with the agreed strategic direction. The Board is kept appraised of personnel, awareness, research programme and budgetary issues.

Public bene t

The Trustees con fi rm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public bene fi t including (PB2 Public Bene fi t: Running a Charity).

Key management personnel and remuneration policy

Orchid is committed to attracting and retaining talented staff. Staff are kept fully informed of the organisation’s strategy and objectives, and individual performance is reviewed throughout the year. Learning and development remain a priority. Temporary and volunteer personnel are engaged for speci fi c tasks to ensure a balanced approach to managing administration, awareness campaigns, support services and fundraising.

The key management personnel comprise the Trustees and the Chief Executive. Trustees do not receive remuneration. The salary of the Chief Executive is set by the Chairman of the Board of Trustees in consultation with the Finance Committee and Board of Trustees following an annual review of performance. The Charity uses Royal College of Nursing (RCN) bands, NHS pay scales and Charity Salary Surveys for benchmarking salaries of all other members of staff. Annual salary increases for staff are discussed and where applicable approved by the Finance Committee and Board of Trustees.

Research Programme: Peer Review

Given the importance of expert independent peer review in validating applications for new research grants and the veri fi cation of outcomes, a Scienti fi c Advisory Board provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and ef fi ciency of research that the Charity currently funds or may consider funding.

Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

42

Internal control and risk management

Orchid is committed to active management of risk. Risk management is incorporated into governance and management structures, planning processes and all aspects of service delivery. Orchid produces a risk register which identi fi es risk and allocates responsibility for managing areas of risk to named individuals. Following Charity Commission recommendations the risk register identi fi es risks under the following headings:

Governance and compliance Operational Financial

Research

Environmental/external Quality assurance

less than annually by the Finance Committee and Board of Trustees. They direct the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

Several other policies, therefore, deal with risk management and risk assessment e.g. Health and Safety Policy, Safeguarding etc. All policies are reviewed regularly and updated in line with changes in legislation, regulation and best practice. New policies are introduced as required.

Speci fi c risks which, if materialised, would have had a signi fi cant impact on the Charity have been identi ed. These are as follows:

Governance and compliance

Ability to maintain a Board of Trustees with all the skills required to ensure that all aspects of governance are adhered to

Mitigation

Each identi fi ed risk is assessed in terms of likelihood and impact and then weighted giving a gross risk rating. Actions to minimise each risk are identi fi ed and responsibility for monitoring these is given to named individuals. The strength of each risk management strategy is given a numeric rating enabling the net risk to be calculated.

management personnel and advisers are of a calibre to ensure that the Charity is aware of and compliant with regulatory and similar requirements

The Chief Executive is responsible to the Board for the management and implementation of the risk management strategy and reports to the Board on progress towards mitigating each risk. Risk is reviewed quarterly by staff and not

OUR IMPACT 43

Operational

Attracting, developing and retaining talented staff in a competitive employment market

Mitigation

Financial

Economic pressures, competition, fundraising regulatory environment and consumer behaviour changes leading to a signi fi cant fall in income

Mitigation

Research

Orchid’s Research Programme fails to deliver results

Mitigation

Environmental / external

Changes in government policy or budgets, Charity sector regulations, or reform of the NHS or changes to the research environment that negatively impact on Orchid’s work

Mitigation

Quality assurance

Patients, their families, health and social professionals, educators and other interested parties given inaccurate, poor quality information leading to reputational damage

Mitigation

44 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

Financial review

Results for the year

Income for the year ended 30 September 2023 totalled £730,024 (2022: £841,808). After total expenditure of £634,721 (2022: £740,252), the year’s activities show a net surplus of £95,303 (2022: surplus of £101,556). Total reserves at the end of the year amounted to £637,139 (2022: £541,836).

Reserves policy

Designated reserves are funds that have been earmarked by the Trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £121,808 to help fund the costs of increased

organisational capacity with the Charity. Free reserves are distinct from funds that have been

earmarked or ‘designated’ for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensure the Charity’s core activity of funding research and awareness during a period of sustained unforeseen dif fi culty and a proportion must be in a readily realisable form. The calculation of the required level of reserves is an integral part of the Charity’s planning, budgeting and forecast cycle. It should take into account:

The available free reserves net of tangible and intangible fi xed assets are £157,287 (2022: £162,113). It is the Charity’s policy to maintain free reserves of approximately 3–4 months of operating costs. At current levels of expenditure this equates to £155,000–£212,000.

Formal statements Statement of Trustees’ responsibilities

The Trustees, who are also directors of Orchid Cancer Appeal for the purposes of company law, are responsible for preparing the Trustees’ Report and the fi nancial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires Trustees to prepare fi nancial statements for each fi nancial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these fi nancial statements, the Trustees are required to:

OUR IMPACT 45

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the fi nancial position of the charitable company and enable them to ensure that the fi nancial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and fi nancial information included on the Charity’s website. Legislation in the United Kingdom governing the preparation and dissemination of fi nancial statements may differ from legislation in other jurisdictions.

Independent Examiner’s information

So far as each of the directors at the time the Trustees’ report is approved is aware:

a) there is no relevant information of which the examiner is unaware; and

b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant independent examination information and to establish that the examiners are aware of that information.

The examiner, Moore Kingston Smith LLP, has been authorised for appointment in accordance with Section 485 of the Companies Act 2006.

Moore Kingston Smith LLP has indicated its willingness to continue in of fi ce and in accordance with the provisions of the Companies Act, it is proposed that it will be re-appointed examiner for the ensuing year.

Signed on behalf of the Trustees

C S Osborne Chairman of Trustees 12/06/24

The fi nancial statements have been prepared in accordance with the provisions of the Companies Act 2006 Part 15 relating to small companies, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Memorandum and Articles of Association of the Company.

46 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

Independent Examiner’s Report to the Trustees of Orchid Cancer Appeal

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 September 2023.

Responsibilities and basis of report

As the charity’s trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (“the 2006 Act”).

Having satis fi ed myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 (“the 2011 Act”). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145 (5) (b) of the 2011 Act.

Independent examiner’s statement

Since the Company’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I con fi rm that I am quali fi ed to undertake the examination because I am a member of the Association of Chartered Certi fi ed Accountants which is one of the listed bodies.

I have completed my examination. I con fi rm that no matters have come to my attention in connection with the examination giving me cause to believe:

  1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or

  2. the accounts do not accord with those records; or

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Adam Fullerton FCA DChA

Date: 19 June 2024

For and on behalf of Moore Kingston Smith LLP Chartered Accountants 6th Floor, 9 Appold Street, London EC2A 2AP

  1. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or

  2. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities.

OUR IMPACT

47

Statement of nancial activities

(incorporating an income and expenditure account) For the year ended 30 September 2023

Unrestricted

Note
Total
£
Income from:
Donations and Legacies
2
310,632
Charitable Activities
4
-
Trading Activities
272
Investment income
1,120
Total income
312,024
Expenditure on:
Raising funds
Fundraising
(donations and grants)
5
163,449
Charitable Activities
Education and Awareness
5
131,385
Research
5
15,605
Total expenditure
310,439
Net income / (expenditure) and net
movement in funds
5,6
1,585
Reconciliation of funds
Total funds brought forward
297,016
Total funds carried forward
298,601		 Year ended
Year ended
Restricted30 September30 September
Total
2023
2022
£
£
£
257,150
567,782
674,700
160,850
160,850
166,673
-
272
309
-
1,120
126
418,000
730,024
841,808
-
163,449
185,431
288,636
420,021
376,842
35,646
51,251
177,979
324,282
634,721
740,252
93,718
95,303
101,556
244,820
541,836
440,280
338,538
637,139
541,836

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 14 to the nancial statements.

48 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

Balance sheet

As at 30 September 2023

Note
Fixed Assets
Tangible Assets
10
Intangiblefxed assets
11
Current Assets
Cash at bank and in hand
Debtors
12
CREDITORS
Amounts due within one year
13
Net Current Assets
Total Assets less Current Liabilities14
NET ASSETS
Represented by:
15
General Unrestricted Funds
Designated Funds
Restricted funds		 30 September
2023
£
£
3,340
16,166
630,903
67,957
698,860
(81,227)
617,633
637,139
637,139
176,793
121,808
298,601
338,538
637,139		 30
£
590,444
108,806
699,250
(170,509)
175,208
121,808		 September
2022
£
3,891
9,204
528,741
541,836
541,836
297,016
244,820
541,836

The company is limited by guarantee.

For the year ending 30 September 2023 the charitable company was entitled to exemption from statutory audit under Section 477 of the Companies Act 2006 relating to small companies.

No notice from Trustees requiring an audit has been deposited under Section 476 of the Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

The fi nancial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The fi nancial statements were approved by the Board and authorised for issue on 12/06/24 and signed on its behalf by:

Mr C S Osborne Company number 3963360

OUR IMPACT

49

Statement of cash ows

For the year ended 30 September 2023

2023 2022 £ £ £ £ Cash fl ows from operating activities: Net income for the year 95,303 101,556 Adjustments for: Depreciation charges 5,338 1,944 Interest (1,120) (126) Decrease / (increase) in debtors 40,849 (31,481) (Decrease) / increase in creditors (89,282) 21,639 Net cash provided by operating activities 51,088 93,532 Cash fl ows from investing activities: Interest 1,120 126 Purchase of fi xed asset (11,749) (12,068) Net cash (used in) investing activities (10,629) (11,942) Change in cash and cash equivalents in the year 40,459 81,590 Cash and cash equivalents at the beginning of the year 590,444 508,854 Cash and cash equivalents at the end of the year 630,903 590,444 Analysis of cash and cash equivalents Cash at bank and in hand 630,903 590,444 630,903 590,444

50 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

Notes to the nancial statements

1. Accounting policies

For the year ended 30 September 2023

Basis of Preparation

These fi nancial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charity is a public bene fi t entity for the purposes of FRS 102 and therefore has also prepared the fi nancial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Charities Act 2011.

Going Concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these fi nancial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these fi nancial statements. In particular the trustees have considered the charities forecasts and projections and have taken account of pressures on donation income. After making enquiries the trustees have concluded there is a degree of uncertainty around donation income for 2023/24 however that there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The charity therefore continues to adopt the going concern basis in preparing its fi nancial statements.

The trustees con fi rm that there are no material uncertainties about the ability of the charity to continue as a going concern. The charity, therefore, continues to adopt the going concern basis in preparing its fi nancial statements.

Functional Currency

The functional currency is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity operates. The fi nancial statements are also presented in pounds sterling, rounded to the nearest £1.

Taxation

The Charity has suffered no tax charge as it is not subject to UK Corporation tax on its charitable activities.

Depreciation

Depreciation is provided at the following annual rates so as to write off the cost of each asset over its useful life. Assets with a purchase consideration in excess of £1,000 are capitalised.

Computer and Of fi ce Equipment - 33[1] /3% on written down value.

Intangible fi xed assets

Intangible fi xed assets are included in the balance sheet at original cost less accumulated amortisation. Amortisation is provided on a straight line basis calculated to write down the cost of all intangible assets to their estimated residual values over the number of years of expected use. Assets

Website - 20% on straight line value

Funds Accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the Charity and which have not been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for speci fi c purposes.

Restricted funds are funds subject to speci fi c restrictions imposed by donors or by the nature of the appeal.

Income

Income becoming available to the Charity is recognised when there is entitlement to the income, probability of receipt and amounts can be measured reliably as per FRS102 SORP.

Gifts in kind are valued and brought in as income and the appropriate expenditure, when the items are used/distributed. The values attributable to gifts in kind are an estimate of the gross value to the organisation, where quanti fi able. Where this intangible income relates to project activities, it is included as an activity in furtherance of the Charity's objects.

Expenditure

Cost of raising funds includes costs

associated with the fund-raising events in furtherance of the Charity’s objects.

Charitable expenditure includes costs associated with particular activities in furtherance of the Charity’s objects.

Governance costs are those incurred in connection with the management of the Charity’s assets, organisational administration, and compliance with constitutional and statutory requirements and are included within support costs.

Charitable expenditure comprises direct expenditure including direct staff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been

OUR IMPACT 51

allocated to activities on a basis consistent with use of the resources.

Grants payable are charged when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are ful fi lled. Grants offered subject to conditions which have not been met at the balance sheet date are noted as a commitment, but not accrued as expenditure.

Financial Instruments

The charitable company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ of FRS 102 to all of its fi nancial instruments. Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the fi nancial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. With the exceptions of prepayments, deferred income and amounts owed to or from HMRC. All other debtor and creditor balances are considered to be basic fi nancial instruments under FRS 102.

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Cash and Cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and in hand and term deposits with an original maturity date of three months or less. For the purpose of the statement of cash fl ows, cash and cash equivalents consist of cash and cash equivalents as de ned above.

Creditors

Short term trade creditors are measured at the transaction price. Other fi nancial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Deferred income represents grants, contract funding and training fees relating to future periods.

Pension Scheme

The Charity operates a de fi ned contribution stakeholder pension scheme. The amount charged to the statement of fi nancial activities in respect of pension costs is the Charity's contributions payable in the year. The assets of the scheme are held separately from the Charity. There was no outstanding liability owed to the scheme at the end of the current or prior years.

Employee Bene fi ts

The cost of short-term employee bene fi ts are recognised as a liability and an expense. The cost of any material unused holiday entitlement is recognised in the period in which the employee’s services are received.

Critical accounting estimates and areas of judgement

In the view of the Trustees in applying the accounting policies adopted, no judgements were required that have signi fi cant effect on the amounts recognised in the fi nancial statements nor do any estimates or assumptions carry a signi fi cant risk of material adjustment in the next fi nancial year.

52 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

2. Donations

Current year Year ended Year ended 30 September 2023 30 September 2022 Restricted Unrestricted Total Total £ £ £ £ Individuals 500 57,512 58,012 186,887 Legacies - 19,147 19,147 100,000 Corporates - 76,601 76,601 36,814 Trusts and Foundations 256,650 7,978 264,628 209,721 Fundraising Events - 149,394 149,394 141,278 Total 257,150 310,632 567,782 674,700 Prior year Year ended 30 September 2022 Restricted Unrestricted Total £ £ £ Individuals 68,800 118,087 186,887 Legacies - 100,000 100,000 Corporates - 36,814 36,814 Trusts and Foundations 165,121 44,600 209,721 Fundraising Events - 141,278 141,278 Total 233,921 440,779 674,700

OUR IMPACT

53

3. Fundraising events

Current year Year ended Year ended 30 September 2023 30 September 2022 Restricted Unrestricted Total Total £ £ £ £ Cycling events - 2,296 2,296 658 Running events - 68,852 68,852 68,646 Third party organised events - 63,886 63,886 62,806 Trek - 92 92 - Other - 14,268 14,268 9,168 Total - 149,394 149,394 141,278 Prior year Year ended 30 September 2022 Restricted Unrestricted Total £ £ £ Cycling events - 658 658 Running events - 68,646 68,646 Third party organised events - 62,806 62,806 Other - 9,168 9,168 Total - 141,278 141,278

4. Charitable activities

Current year Year ended Year ended 30 September 2023 30 September 2022 Restricted Unrestricted Total Total £ £ £ £ The National Lottery Community Fund 160,850 - 160,850 166,673 RC England-wide Total 160,850 - 160,850 166,673 Prior year Year ended 30 September 2022 Restricted Unrestricted Total £ £ £ The National Lottery Community Fund 166,673 - 166,673 RC England-wide Total 166,673 - 166,673

54 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

5. Total expenditure

Year ended Year ended Cost of Education and 30 September 2023 30 September 2022 raising funds Awareness Research Total Total £ £ £ £ £ Grants - - 18,519 18,519 149,222 Staff costs 80,542 162,814 21,298 264,654 240,059 Fundraising expenses 39,663 - - 39,663 68,941 Information materials - 126,256 - 126,256 98,605 Direct costs - 33,511 - 33,511 38,393 120,205 322,581 39,817 482,603 595,220 Support costs Depreciation 1,499 3,443 396 5,338 1,944 Other 33,124 76,047 8,759 117,930 117,654 Governance - staff costs 6,725 13,596 1,778 22,099 18,936 Governance - examiners fees 1,896 4,354 501 6,751 6,498 43,244 97,440 11,434 152,118 145,032 Total expenditure 163,449 420,021 51,251 634,721 740,252 Prior year 185,431 376,842 177,979 740,252

6. Grants awarded

Year ended Year ended 30 September 2023 30 September 2022 Total Total £ £ Grant commitments brought forward 126,617 87,576 Institutional grants for medical research awarded during year/period Orchid Study and Travel Awards (2023: 2 individuals, 2022: 2 individuals) 1,000 2,000 Barts and London School of Medicine 35,646 144,652 Write off (18,128) Payments made during period/year (108,489) (107,611) Grant commitments carried forward 36,646 126,617 Payable less than one year 36,646 126,617 Payable two to fi ve years - -

OUR IMPACT

55

7. Net expenditure for the period

Year ended Year ended This is stated after charging: 30 September 2023 30 September 2022 Total Total £ £ Depreciation 2,400 1,944 Independent examiners’ remuneration: Independent examination 5,435 5,415 Trustees’ remuneration Nil Nil

8. Staff costs and numbers

Year ended Year ended Staff costs were as follows: 30 September 2023 30 September 2022 Total Total £ £ Salaries and wages 235,955 205,290 Social security costs 18,666 16,414 Pension contributions 2,122 1,616 256,743 223,320 Consultant costs 30,010 35,675 Total cost 286,753 258,995

During the year ended 30 September 2023, 1 employee earned more than £60,000 (Year to 30 September 2022: 1). The pension contribution paid in respect of this employee totalled £Nil (2022: £Nil)

The key management personnel of the charity comprise the trustees and the chief executive.

The charity trustees do not receive remuneration. The total remuneration of the chief executive was £83,579 (year ended 30 September 2022: £78,802).

The number of employees whose emoluments amounted to over £60,000 in the year (exclusive of employer pensions and employer National Insurance contributions) was as follows:

2023 2022 No . No. £60,000–£69,999 - 1 £70,000–£79,999 1 -

The average number of employees during the year was 7.4 (2022: 7.5)

The average number of employees during the year on a headcount basis was as follows:

2023 2022 No . No. Fundraising 1.7 1.7 Education and Awareness 5.4 5.5 Grant support 0.3 0.3 Overall average 7.4 7.5

Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

56

9. Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

10. Tangible xed assets

Computer and Year ended Year ended of fi ce equipment 30 September 2023 30 September 2022 Total Total £ £ £ Cost At the start of the period 10,179 10,179 7,315 Additions 745 745 2,864 At the end of the period 10,924 10,924 10,179 Depreciation At the start of the period 6,288 6,288 4,344 Charge for Period 1,296 1,296 1,944 At the end of the period 7,584 7,584 6,288 Net book value At the end of the period 3,340 3,340 3,891 At the start of the period 3,891 3,891 2,971 11. Intangible fi xed assets Website Year ended Year ended development 30 September 2023 30 September 2022 Total Total £ £ £ Cost At the start of the period 9,204 9,204 - Additions 11,004 11,004 9,204 At the end of the period 20,208 20,208 9,204 Amortisation At the start of the period - - - Charge for Period 4,042 4,042 - At the end of the period 4,042 4,042 - Net book value At the end of the period 16,166 16,166 9,204 At the start of the period 9,204 9,204 -

OUR IMPACT

57

12. Debtors

Year ended Year ended 30 September 2023 30 September 2022 Total Total £ £ Prepayments 7,439 10,071 Other debtors and accrued income 60,518 98,735 67,957 108,806

13. Creditors: amounts due within one year

Year ended Year ended 30 September 2023 30 September 2022 Total Total £ £ Grants Payable 35,646 126,617 Trade and Other Creditors 11,424 11,113 Accruals 34,157 32,779 81,227 170,509

14. Movements in funds

Brought forward Income Expenditure Carried forward £ £ £ £ Unrestricted General 175,208 312,024 (310,439) 176,793 Designated – Development 121,808 - - 121,808 Total unrestricted 297,016 312,024 (310,439) 298,601 Restricted The National Lottery Community Fund - 40,796 160,850 (172,616) 29,030 Overcoming the Barriers - Male Cancer Nurse Information Specialist 3,600 16,000 (19,600) The Innovation Research Project 154,180 1,957 - 156,137 Penile Cancer Peer Support 1,000 760 (195) 1,565 Education and Awareness 33,655 19,858 (49,513) 4,000 Student Study and Travel Scholarships 4,729 - (1,000) 3,729 - Roadshows 6,860 37,875 (44,735) Robert Lane Tissue Bank - 48,700 (35,646) 13,054 Nurse Led Services - 2,000 - 2,000 Four nations penile cancer programme - 130,000 (977) 129,023 Total restricted 244,820 418,000 (324,282) 338,538 Total funds 541,836 730,024 (634,721) 637,139

58 Orchid Cancer Appeal | Annual report and nancial statements 2022–2023

14. Movements in funds (continued)

Prior year movements in funds Brought forward Income Expenditure Carried forward £ £ £ £ Unrestricted General 157,158 441,214 (423,164) 175,208 Designated – Development 121,808 - - 121,808 Total unrestricted 278,966 441,214 (423,164) 297,016 Restricted The National Lottery Community Fund - RC England-wide 32,445 166,673 (158,322) 40,796 Male Cancer Nurse Information Specialist - other funders 8,252 12,100 (16,752) 3,600 The Innovation Research Project 92,800 68,700 (7,320) 154,180 Penile Cancer Peer Support - 8,500 (7,500) 1,000 Education and Awareness 5,000 58,950 (30,295) 33,655 Student Study and Travel Scholarships 6,729 - (2,000) 4,729 Roadshows 2,860 42,871 (38,871) 6,860 Robert Lane Tissue Bank - 42,800 (42,800) - Young Person’s Testicular Cancer Project 3,228 - (3,228) - City of London Corporation 10,000 - (10,000) - Total restricted 161,314 400,594 (317,088) 244,820 Total funds 440,280 841,808 (740,252) 541,836

General funds are unrestricted funds available for use at the Trustees’ discretion in furtherance of the general activities of the charity and which have not been designated for other purpose.

Designated Development funds represent monies set aside at the Trustees’ discretion to be used to help fund the costs related to increasing the organisational capacity of the charity.

Designated Awareness funds represent monies set aside at the Trustees’ discretion to be used to help fund speci fi c awareness activities.

OUR IMPACT

59

15. Analysis of net assets between funds

Unrestricted Restricted Total funds at funds funds 30 September 2023 £ £ £ Fixed Assets 3,340 - 3,340 Current Assets 376,490 338,538 715,028 Creditors due within one year (81,229) - (81,229) Net assets at 30 September 2023 298,601 338,538 637,139 Prior year analysis of net assets between funds Fixed Assets 13,095 - 13,095 Current Assets 454,430 244,820 699,250 Creditors due within one year (170,509) - (170,509) Net assets at 30 September 2022 297,016 244,820 541,836

16. Related party transactions

Aggregate donations of £500 were received from trustees in the year ended 30 September 2023. (Year to 30 September 2022: £52,500).

17. Financial commitments

For the year ended 30 September 2023, the charity was committed to making the following future payments under non cancellable operating leases.

Year ended Year ended 30 September 2023 30 September 2022 Total Total Land and buildings £ £ Expiring within one year 15,637 14,184 Expiring within two to fi ve years - - 15,637 14,184

18. Capital commitments

At the year ended 30 September 2023, the charity had no capital commitments (2022: £9,204).

ORCHID FIGHTING MALE CANCEFI